... DALLAS Nov. 6 /- Access Pharmaceuticals I...The presentation will be available via webcast and can be accessed at:...About ProLindac(TM): ...ProLindac is a novel DACH platinum prodrug which has been shown to be...

DALLAS, Nov. 6 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc.
(OTC Bulletin Board: ACCP) announced today that it will make a presentation
at the Rodman & Renshaw Annual Global Investment Conference to be held
November 10-12, 2008 at the New York Palace Hotel. Jeffrey B. Davis, CEO of
Access is scheduled to speak on Tuesday, November 11, 2008 at 2:50 p.m.
Eastern Time, and will give a corporate overview and discuss the Company's
product opportunities.

ProLindac is a novel DACH platinum prodrug which has been shown to be
active in a wide variety of solid tumors in both preclinical models and in
human trials. Access believes that ProLindac's unique molecular design
potentially could eliminate some of the toxic side effects seen in the
currently marketed DACH platinum, Eloxatin, which has sales in excess of $2
billion.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company
that develops and commercializes propriety products for the treatment and
supportive care of cancer patients. Access' products include Prodac(TM),
currently in Phase 2 clinical testing of patients with ovarian cancer, and
MuGard(TM) for the management of patients with mucositis. The company also
has other advanced drug delivery technologies including
Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its
proprietary nanopolymer delivery technology based on the natural vitamin
B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which
acts as an anti-angiogenesis factor and is targeted to breast cancer;
Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of
solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that
combines multiple modes of action to overcome drug resistance. Access is
also developing Phenylbutyrate ("PB"), an HDAC inhibitor and
differentiating agent currently a Phase 2 clinical candidate. For
additional information on Access Pharmaceuticals, please visit our website
at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as
amended, and that involve risks and uncertainties. These statements include
those relating to: early results from our clinical trial, Access' plans to
continue and initiate clinical trials, the value of its products in the
market, its ability to achieve clinical and commercial success and its
ability to successfully develop marketed products. These statements are
subject to numerous risks, including but not limited Access' need to obtain
additional financing in order to continue the clinical trial and operations
and to the risks detailed in Access' Annual Reports on Form 10-K and other
reports filed by Access with the Securities and Exchange Commission.

(Date:9/22/2017)... ... September 22, 2017 , ... Brain State Technologies®, a leading ... proceeds will be used to fund production of the company’s new B2v2® brainwave ... by nearly 1,000%. , The B2v2 is the world’s first brain-mirroring wellness product ...

(Date:9/21/2017)... ... September 21, 2017 , ... ... includes executive, engineering and manufacturing functions to The LaunchPort™ Accelerator at the City ... a full range of manufacturing and business services to its Residents. , ...

(Date:9/21/2017)... ... September 21, 2017 , ... ... research sector professionals, has announced the addition of 5 new courses to its ... - Compliance with Regulation 21 CFR Part 11 on Electronic Records and Electronic ...

(Date:9/20/2017)... ... September 20, 2017 , ... ... appointed Vishwas Paralkar to the role of chief scientific officer. In this role, ... report to Cybrexa’s president and CEO, Per Hellsund. , “I was impressed with ...

(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...

(Date:4/5/2017)... SEATTLE , April 5, 2017 The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...